Alignment Healthcare president Dawn Maroney sells $4.3 million in stock

Published 07/03/2025, 01:38
Alignment Healthcare president Dawn Maroney sells $4.3 million in stock

Dawn Christine Maroney, the President of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently executed a significant stock sale. On March 6, Maroney sold 278,917 shares of common stock, generating approximately $4.3 million. The shares were sold at a weighted-average price of $15.53 per share, with individual transactions ranging between $15.12 and $16.065 per share. The sale comes as ALHC trades near its 52-week high of $16.25, having delivered an impressive 183% return over the past year. InvestingPro analysis shows the stock is currently fairly valued, with additional insights available in the comprehensive Pro Research Report.

This transaction was prompted by the need to cover tax withholding obligations related to the vesting of performance share units (PSUs). These PSUs were awarded based on the company’s performance metrics, including health plan revenue growth and adjusted EBITDA, which exceeded specified targets. The strong performance is reflected in ALHC’s remarkable 48% revenue growth over the last twelve months, despite operating with moderate debt levels. The acquisition of 1,020,442 shares on March 4 was part of this vesting process, with half of the PSUs becoming fully vested on the acquisition date and the remaining half scheduled to vest on December 31, 2025, contingent on Maroney’s continued service to the company. For deeper insights into ALHC’s financial health and growth prospects, access the full suite of metrics on InvestingPro.

In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16 compared to the forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million against the expected $674.97 million. Full-year 2024 revenue was reported at $2.7 billion, marking a 48% increase year-over-year. Alignment Healthcare achieved its first year of adjusted EBITDA profitability, a significant milestone for the company. Looking ahead, the company has provided guidance for 2025, forecasting revenue between $3.72 billion and $3.78 billion and adjusted gross profit to range from $415 million to $445 million.

In addition to the earnings report, Raymond (NSE:RYMD) James analyst John Ransom increased the price target for Alignment Healthcare to $19.00, citing the company’s robust performance in the fourth quarter. Piper Sandler also raised its price target to $21.00, maintaining an Overweight rating and expressing confidence in Alignment Healthcare’s strategies for growth. Both firms highlighted the company’s ability to scale its business model and deliver consistent, competitive, and cost-effective products across different markets. These developments reflect a promising outlook for Alignment Healthcare, as noted by analysts from both Raymond James and Piper Sandler.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.